SCHEMBL1948591

SCHEMBL1948591

CC1C(=O)NCc2ccc(Br)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
PNMT P11086 5/20 0.42
ADRA2A P08913 4/20 0.42
ADRA2B P18089 3/20 0.42
ADRA2C P18825 3/20 0.42
CMA1 P23946 1/20 0.41
AHR P35869 1/20 0.41
PARP10 Q53GL7 2/20 0.39
PARP1 P09874 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
TDP2 O95551 1/20 0.36
PARP11 Q9NR21 1/20 0.36
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9571041 0.72 HTR2A (0.50) HTR2AHTR2CHTR2BPNMTADRA2A
SCHEMBL31219834 0.70 PGR (0.45) CMA1AHRPOLBBRD4
SCHEMBL29891547 0.70 PGR (0.53) ALDH1A1POLBBRD4
SCHEMBL3519770 0.70 PGR (0.53) ALDH1A1POLBBRD4
SCHEMBL2239581 0.70 PGR (0.45) CMA1AHRPOLBBRD4
SCHEMBL1854240 0.70 HTR2A (0.44) HTR2AHTR2CHTR2BPNMTADRA2A
SCHEMBL4263893 0.70 HTR2A (0.38) HTR2AHTR2CHTR2BPNMTADRA2A
SCHEMBL1851272 0.68 PIM1 (0.50) HTR2BPARP10PARP11ALDH1A1POLB
Hydrochloric Acid SCHEMBL29133384 0.68 HTR2A (0.71) HTR2AHTR2CHTR2BPNMTADRA2A
SCHEMBL19238915 0.67 HTR2A (0.35) HTR2AHTR2CHTR2BPNMTADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110136842-A1 Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers MERCK SHARP & DOHME CORP. 2011-06-09 US disclosed
US-20110136842-A1 Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers MERCK SHARP & DOHME CORP. 2011-06-09 US disclosed
US-20110136842-A1 Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers MERCK SHARP & DOHME CORP. 2011-06-09 US disclosed
WO-2010017048-A1 SUBSTITUTED DIHYDROISOQUINOLINONE AND ISOQUINOLINEDIONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136842-A1 Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers CACNA1D, TRPV1, CACNA1S HTR2A 319/4885HTR2C 239/4885HTR2B 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.